Sigma Planning Corp Nektar Therapeutics Transaction History

Sigma Planning Corp

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Jan 31, 2019	SELL	$30.43 - $56.65 $203,941 - $379,668	-6,702 Closed	0 $0
Q3 2018 Nov 07, 2018	BUY	$46.46 - $68.49 $19,513 - $28,765	420 Added 6.69%	6,702 $409,000
Q2 2018 Aug 02, 2018	BUY	$46.25 - $104.45 $290,542 - $656,154	6,282 New	6,282 $307,000

147

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $201M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Sigma Planning Corp, based on Form 13F filings with the SEC.

Stay updated on Sigma Planning Corp with notifications on news.